Skandinaviska Enskilda Banken Ab (Publ) Vanda Pharmaceuticals Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 10, 2022	SELL	$15.69 - $21.14 $710,443 - $957,219	-45,280 Closed	0 $0
Q3 2021 Nov 10, 2021	SELL	$15.35 - $21.27 $956,612 - $1.33 Million	-62,320 Reduced 57.92%	45,280 $776,000
Q4 2020 Feb 11, 2021	SELL	$9.77 - $13.81 $204,193 - $288,629	-20,900 Reduced 16.26%	107,600 $1.41 Million
Q3 2020 Nov 12, 2020	SELL	$9.32 - $12.02 $271,212 - $349,782	-29,100 Reduced 18.46%	128,500 $1.24 Million
Q2 2020 Aug 13, 2020	BUY	$9.66 - $12.02 $79,212 - $98,564	8,200 Added 5.49%	157,600 $1.8 Million
Q1 2020 May 13, 2020	BUY	$7.5 - $16.8 $1.12 Million - $2.51 Million	149,400 New	149,400 $1.55 Million

155

43.7M

33.8K

28.7K

Ticker VNDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,561,500
Market Cap $252M
Description
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under developme...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.